Results 251 to 260 of about 967,275 (342)

Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults. [PDF]

J Immunol
Silva-Moraes V, Reis LR, Ross TM.
europepmc   +1 more source

HIV‐1 viral load and reservoir size remain stable following SARS‐CoV‐2 mRNA vaccination in people with HIV

HIV Medicine, EarlyView.
Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri, Bianca B Jütte, Jan Vesterbacka, Soo Aleman, Hans‐Gustaf Ljunggren, Marcus Buggert, J Peter Svensson, Anders Sönnerborg, Piotr Nowak   +8 more
wiley   +1 more source

Next-Generation Influenza Vaccines and the Pandemic Horizon: Challenges, Innovations, and the Road Ahead. [PDF]

Vaccines (Basel)
Taaffe J, Lambach P, Gsell P, Ghiga I, Goldin S.   +4 more
europepmc   +1 more source

Influenza vaccines in immunosuppressed adults with cancer.

Cochrane Database of Systematic Reviews, 2018
R. Bitterman, N. Eliakim‐Raz, I. Vinograd, Anca Zalmanovici Trestioreanu, L. Leibovici, M. Paul   +5 more
semanticscholar   +1 more source

Highlights of 2025: advances in germinal centers

Immunology &Cell Biology, EarlyView.
Graphical summary of research advances made in 2025 in germinal center (GC) biology. GCB, germinal center B cells; Tfh, T follicular helper cell; APC, antigen‐presenting cell; FDC, follicular dendritic cell; SHM, somatic hypermutation. Created in BioRender. Webb, L. (2026) https://BioRender.com/bn9jx9v.
Louise MC Webb, Michelle A Linterman
wiley   +1 more source

Comparison of safety and immunogenicity between high-dose and low-dose quadrivalent influenza vaccines in children aged 6-35 months in China: A randomized, double-blind clinical study. [PDF]

Hum Vaccin Immunother
Guo X, Li J, Dong X, Xing K, Xu X, Xu W, Wang C, Li K, Gao X, Qiu Y, Guo Z, Xu W, Zhao C, Ma Y, Wu Y, Liu X, Li G.   +16 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Safety of COVID-19 and influenza vaccines in children and adolescents with immunocompromised or autoimmune conditions: Findings from the Canadian National Vaccine Safety (CANVAS) network. [PDF]

Hum Vaccin Immunother
Turner C, Vanderkooi OG, Kellner JD, Shulha HP, Muller MP, Sadarangani M, Isenor JE, Marty K, Soe P, Kiely M, Valiquette L, McGeer A, Bettinger JA.   +12 more
europepmc   +1 more source

Inducing Antigen‐Specific and Functional Immune Responses in Mice Toward Bovine Herpesvirus 1 and Bovine Respiratory Syncytial Virus by Chimeric Peptides Delivered by Bovine Herpesvirus 4‐Based Vector

Immunology, EarlyView.
Bovine Alphaherpesvirus 1 (BoHV‐1) and Bovine respiratory syncytial virus (BRSV) are major drivers of respiratory disease in cattle. (A) To target both pathogens, two chimeric antigens—membrane‐linked and secreted—combining BoHV‐1 glycoprotein D and BRSV fusion glycoprotein were designed and expressed using recombinant BoHV‐4‐based vectors.
Antonino Di Lorenzo, Sergio Minesso, Chiara Cossu, Valentina Franceschi, Elisabetta Bolli, Vittorio Madia, Laura Conti, Gaetano Donofrio   +7 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source